PIF Peptide Modulates Immune Tolerance Without Pathogen Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as multiple sclerosis, type 1 diabetes, graft-versus-host disease, and inflammatory bowel disease are inadequate, as they either fail to reverse autoimmune damage or come with significant side effects like opportunistic infections and tumor relapse, and there is a need for a therapy that can induce immune tolerance without compromising the ability to respond to pathogens.
Innovation Solution
A pre-implantation factor (PIF) peptide with immune-modulating and anti-inflammatory properties is administered to modulate the immune system, affecting cellular immunity and cytokine profiles, thereby preventing or treating autoimmune disorders by creating a tolerogenic state without toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune suppressive drugs (steroids and Cyclosporin A) are used for GVHD prophylaxis and therapy, then graft acceptance is improved, but patients become vulnerable to opportunistic infections and tumor relapse
Solution Approach 1:
The patent introduces PIF-1 as an intermediary substance that mediates between the graft and host immune systems. PIF-1 creates a tolerogenic state that accepts the graft while preserving pathogen recognition capabilities, unlike conventional immune suppressive drugs that broadly suppress all immune responses. The peptide acts as a selective modulator that distinguishes between alloreactive T cells (which should be suppressed) and pathogen-responsive T cells (which should remain functional).
Solution Approach 2:
The patent changes the immunological parameters by introducing PIF-1, which alters the functional state of T cells from a activated/proliferative state to a tolerogenic state. This parameter change selectively affects alloreactive responses while preserving protective immunity, resolving the contradiction between graft acceptance and infection resistance.
2Reliability
If myeloablative conditioning regimens (high-dose chemotherapy and total-body radiation) are used to eliminate host-derived hematopoietic elements before BMT, then transplant acceptance is improved, but patient toxicity and morbidity increase
Solution Approach 1:
The patent extracts the immune suppression function from the harsh myeloablative conditioning regimen. Instead of using high-dose chemotherapy and radiation to achieve transplant acceptance, the invention introduces PIF-1 as a separate, targeted intervention that provides immune modulation without the toxic effects of conventional conditioning. This separates the graft acceptance function from the toxic elimination of host immune cells.
Solution Approach 2:
The patent replaces the expensive and toxic myeloablative conditioning with a simpler, shorter-acting alternative. PIF-1 is administered as a peptide that provides temporary immune modulation during the critical window for graft acceptance, then is cleared from the system, avoiding the long-term toxicity of chemotherapy and radiation.
3Object-affected harmful factors
If conventional immune suppressive therapy is used for autoimmune diseases, then immune-mediated damage is reduced, but the ability to respond to pathogens is compromised
Solution Approach 1:
The patent applies local quality by creating a tolerogenic state specifically针对 alloreactive or autoreactive T cells while leaving pathogen-responsive T cells unaffected. PIF-1 selectively modulates immune responses based on the activation state and specificity of T cells, providing local suppression where needed (against self or graft antigens) while maintaining global immune competence (against pathogens).
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.